Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.36 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868071 | 1.00 | CASP3 (0.38) | CASP3CTSKTACR1TAOK1TAOK3 | |
| SCHEMBL14158013 | 0.92 | CTSK (0.39) | CASP3CTSKTACR1TAOK1TAOK3 | |
| SCHEMBL4864545 | 0.85 | PSMB5 (0.47) | CTSK | |
| SCHEMBL4868592 | 0.84 | CTSK (0.43) | CTSKTAOK1TAOK3 | |
| SCHEMBL14597704 | 0.82 | CCNA2 (0.39) | CASP3CTSKTACR1TAOK1TAOK3 | |
| SCHEMBL4869933 | 0.80 | KMT2A (0.41) | CTSK | |
| SCHEMBL14597588 | 0.79 | CTSK (0.37) | CASP3CTSKTACR1TAOK1TAOK3 | |
| SCHEMBL14597546 | 0.79 | CTSK (0.38) | CASP3CTSKTACR1TAOK1TAOK3 | |
| SCHEMBL14597592 | 0.79 | CTSK (0.38) | CASP3CTSKTACR1TAOK1TAOK3 | |
| SCHEMBL14597543 | 0.79 | CTSK (0.38) | CASP3CTSKTACR1TAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | claimed |
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-07-28 | — | — | US | claimed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | claimed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390804-B2 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-07-28 | — | — | US | disclosed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164954-A1 | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | ACIN1, CASP7, CASP10 | CASP3 18/4885CTSK 138/4885TACR1 2022/4885 |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP7, CASP10 | CASP3 17/4885CTSK 396/4885TACR1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.